IPHA — Innate Pharma SA Balance Sheet
0.000.00%
Last trade - 00:00
- $178.18m
- $173.55m
- €51.90m
- 19
- 10
- 47
- 15
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 219 | 152 | 120 | 101 | 92.5 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5.69 | 13.9 | 13.5 | 31 | 46.5 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 238 | 173 | 138 | 140 | 148 |
Net Property, Plant And Equipment | 11.7 | 11.7 | 10.2 | 8.54 | 6.32 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 401 | 307 | 267 | 208 | 184 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 122 | 45.5 | 79.9 | 41.3 | 39.6 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 184 | 151 | 160 | 154 | 132 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 217 | 156 | 107 | 54.2 | 51.9 |
Total Liabilities & Shareholders' Equity | 401 | 307 | 267 | 208 | 184 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |